Drawing for SATIV

USPTO serial 79276064

SATIV

Reviewed by CopyMark Law Group

Status 603
Filing date
Status date
Registration date
—
Examiner
LOOK, JEFFREY J
Law office
TMO LAW OFFICE 130 - EXAMINING ATTORNEY ASSIGNED

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SATIV?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

MICHAEL T. OLSEN

MICHAEL T. OLSEN Winthrop & Weinstine, P.A.225 South 6th StreetSuite 3500Minneapolis, MN 55402

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and veterinary preparations, namely, for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; herbs for medicinal purposes; medicinal herbs; medicinal oils; medicinal infusions, each of the foregoing for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; pure extracts of medicinal plants and herbs for pharmaceutical use; foodstuffs for medicinal purposes; herb teas for medicinal purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 5, 2026CHLDCHANGE OF OWNER RECEIVED FROM IB—
Feb 5, 2026CHLDCHANGE OF OWNER RECEIVED FROM IB—
Dec 18, 2025ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Feb 13, 2024FINTFINAL DECISION TRANSACTION PROCESSED BY IB—
Jan 22, 2024FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 20, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 23, 2023MAB3ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL—
Jan 20, 2023MAB3ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL—
Jan 17, 2023ABN3ABANDONMENT - AFTER EX PARTE APPEAL—
Jan 17, 2023EXPTEXPARTE APPEAL TERMINATED—
Dec 5, 2022EXFBEXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF—
Aug 17, 2022GNS1NOTIFICATION OF SUBSEQUENT FINAL EMAILED—
Aug 17, 2022GNSFSUBSEQUENT FINAL EMAILED—
Aug 17, 2022CFRCSUBSEQUENT FINAL REFUSAL WRITTEN—
Jul 6, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 5, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 5, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 3, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 3, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 3, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 20, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Nov 9, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 9, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 8, 2021ALIEASSIGNED TO LIE—
Nov 3, 2021ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Nov 3, 2021EXPIEX PARTE APPEAL-INSTITUTED—
Nov 3, 2021JURTJURISDICTION RESTORED TO EXAMINING ATTORNEY—
Nov 3, 2021EXAFEXPARTE APPEAL RECEIVED AT TTAB—
Sep 15, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 15, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Sep 15, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 15, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 27, 2021OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jun 9, 2021OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jun 9, 2021OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
May 3, 2021GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
May 3, 2021GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 3, 2021CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 27, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 26, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 26, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 18, 2020RFNTREFUSAL PROCESSED BY IB—
Sep 28, 2020RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 28, 2020RFRRREFUSAL PROCESSED BY MPU—
Sep 5, 2020RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 4, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 31, 2020DOCKASSIGNED TO EXAMINER—
Jan 16, 2020DOCKASSIGNED TO EXAMINER—
Jan 14, 2020MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 10, 2020DOCKASSIGNED TO EXAMINER—
Jan 10, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 9, 2020REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance